Lebray P
-
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication
-
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.
-
Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.
-
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
-
Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).
-
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).
-
Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".
-
Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.
-
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.
-
FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.
-
Prognostic value of liver fibrosis biomarkers: a meta-analysis.
-
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).
-
Applicability and variability of liver stiffness measurements according to probe position.
-
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication
-
Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.
-
FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C.
-
FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence.
-
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication
-
Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations.
-
Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.
-
A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Key publication
-
Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus.